GlaxoSmithKline

Visual Financials
Company Name: GlaxoSmithKline PLC
Ticker Symbol: GSK
CIK Number: 0001131399
WWW Address: http://www.gsk.com
CEO: Emma N Walmsley
No. of Employees: 99,300
Common Issue Type: CS
Business Description:GlaxoSmithKline PLC incorporated in United Kingdom. The Company creates, discoveres, develops, manufactures and markets pharmaceutical products including vaccines, over-the-counter (OTC) medicines and health-related consumer products.

 
Industry Information: DRUGS - Drug Manufacturers - Major [more like this]
 Price  Day Change  Bid  Ask  Open  High  Low  Volume 
 41.3 Up 0.17 - - 41.42 39.32 38.96 1320681
 Market Cap (mil) Shares Outstanding (mil) Beta EPS DPS P/E Yield 52-Wks-Range
 102,997.8 2,493.9 0.00 1.47 1.98 27.1 5.2 42.37 - 35.90
KEY FIGURES (Latest Twelve Months - LTM)
Yesterday's Close38.98$
PE Ratio - LTM27.1
Market Capitalisation102,997.8mil
Latest Shares Outstanding2,493.9mil
Earnings pS (EPS)1.47$
Dividend pS (DPS)1.98¢
Dividend Yield5.2%
Dividend Payout Ratio1%
Revenue per Employee272,162$
Effective Tax Rate0.2%
Float0.0mil
Float as % of Shares Outstanding%
Foreign Salesmil
Domestic Salesmil
Selling, General & Adm/tive (SG&A) as % of Revenue0.30%
Research & Devlopment (R&D) as % of Revenue0.10%
Gross Profit Margin66.8%
EBITDA Margin28.9%
Pre-Tax Profit Margin0.0%
Assets Turnover53.9%
Return on Assets (ROA)6.3%
Return on Equity (ROE)168.8%
Return on Capital Invested (ROCI)15.3%
Current Ratio0.8
Leverage Ratio (Assets/Equity)13.3
Interest Cover
Total Debt/Equity (Gearing Ratio)5.98
LT Debt/Total Capital82.0%
Working Capital pS-2.23$
Cash pS0.29$
Book-Value pS2.21$
Tangible Book-Value pS-7.47$
Cash Flow pS4.21$
Free Cash Flow pS3.32$
KEY FIGURES (LTM): Price info
Price/Book Ratio18.15
Price/Tangible Book Ratio0.00
Price/Cash Flow9.5
Price/Free Cash Flow12.1
P/E as % of Industry Group74.0%
P/E as % of Sector Segment106.0%
 
Balance Sheet (at a glance) in Millions
DIVIDEND INFO
Type of PaymentCash Payment
Dividend Rate1.98
Current Dividend Yield5.2
5-Y Average Dividend Yield5.0
Payout Ratio1.0
5-Y Average Payout Ratio98.0
Share price performance previous 3 years

Share price performance intraday

 
PRICE/VOLUMEHighLowClose% Price Chg% Price Chg vs. Mkt.Avg. Daily VolTotal Vol
1 Week---0.92,165,0269,020,060
4 Weeks40.3238.3539.53-1.42,229,76442,365,528
13 Weeks42.3738.3540.24-3.12,366,957151,485,303
26 Weeks42.3735.9037.284.62,879,570357,066,781
52 Weeks42.3735.9041.00-4.92,729,125682,281,291
YTD42.3737.60-2.92,655,898286,837,016
Moving Average5-Days10-Days10-Weeks30-Weeks200-DaysBeta (60-Mnth)Beta (36-Mnth)
38.8439.1440.1939.8239.880.000.00
 
GROWTH RATES5-Year
Growh
R² of 5-Year Growth3-Year
Growth
Revenue0.030.20.09
Income-0.080.5-0.25
Dividend0.010.10.01
Capital Spending0.03NA0.49
R&D1.20NA-2.20
Normalized Inc.-3.28NA10.85
 
CHANGESYTD vs.
Last YTD
Curr Qtr vs.
Qtr 1-Yr ago
Annual vs.
Last Annual
Revenue %-7.5-7.50.5
Earnings %-29.8-29.8-9.5
EPS %-29.3-29.3-7.7
EPS $-0.25-0.25-0.25
 
SOLVENCY RATIOS
SHORT-TERM SOLVENCY RATIOS (LIQUIDITY)
Net Working Capital Ratio-7.19
Current Ratio0.8
Quick Ratio (Acid Test)0.4
Liquidity Ratio (Cash)0.35
Receivables Turnover6.3
Average Collection Period57
Working Capital/Equity0.0
Working Capital pS-2.24
Cash-Flow pS4.49
Free Cash-Flow pS3.53
FINANCIAL STRUCTURE RATIOS
Altman's Z-Score Ratio0.82
Financial Leverage Ratio (Assets/Equity)6.0
Debt Ratio44.9
Total Debt/Equity (Gearing Ratio)5.98
LT Debt/Equity4.65
LT Debt/Capital Invested0.0
LT Debt/Total Liabilities77.6
Interest Cover124.1
Interest/Capital Invested0.89
 
VALUATION RATIOS
MULTIPLES
PQ Ratio0.00
Tobin's Q Ratio1.29
Current P/E Ratio - LTM27.10
Enterprise Value (EV)/EBITDA10.04
Enterprise Value (EV)/Free Cash Flow14.79
Dividend Yield5.2
Price/Tangible Book Ratio - LTM0.00
Price/Book Ratio - LTM18.15
Price/Cash Flow Ratio9.5
Price/Free Cash Flow Ratio - LTM12.1
Price/Sales Ratio0.00
P/E Ratio (1 month ago) - LTM19.3
P/E Ratio (26 weeks ago) - LTM14.1
P/E Ratio (52 weeks ago) - LTM14.3
5-Y High P/E Ratio27.8
5-Y Low P/E Ratio17.3
5-Y Average P/E Ratio19.1
Current P/E Ratio as % of 5-Y Average P/E-10
P/E as % of Industry Group74.0
P/E as % of Sector Segment106.0
Current 12 Month Normalized P/E Ratio - LTM19.5
PER SHARE FIGURES
LT Debt pS0.00
Current Liabilities pS0.00
Tangible Book Value pS - LTM-7.47
Book Value pS - LTM2.21
Capital Invested pS16.21
Cash pS - LTM0.29
Cash Flow pS - LTM4.21
Free Cash Flow pS - LTM3.32
Earnings pS (EPS)1.47
 
OPERATING RATIOS
PROFITABILITY RATIOS
Free Cash Flow Margin21.50
Free Cash Flow Margin 5YEAR AVG13.93
Net Profit Margin0.2
Net Profit Margin - 5YEAR AVRG.0.1
Equity Productivity7.07
Return on Equity (ROE)1.7
Return on Equity (ROE) - 5YEAR AVRG.1.4
Capital Invested Productivity1.02
Return on Capital Invested (ROCI)0.2
Return on Capital Invested (ROCI) - 5YEAR AVRG.0.2
Assets Productivity0.50
Return on Assets (ROA)0.1
Return on Assets (ROA) - 5YEAR AVRG.0.1
Gross Profit Margin66.8
Gross Profit Margin - 5YEAR AVRG.0.7
EBITDA Margin - LTM28.9
EBIT Margin - LTM22.9
Pre-Tax Profit Margin0.2
Pre-Tax Profit Margin - 5YEAR AVRG.0.2
Effective Tax Rate0.0
Effective Tax Rate - 5YEAR AVRG.0.0
EFFICIENCY RATIOS
Cash Conversion Cycle
Revenue per Employee272,162
Net Income per Employee31,993
Average Collection Period
Receivables Turnover6.3
Day's Inventory Turnover Ratio
Inventory Turnover1.9
Inventory/Sales17.8
Accounts Payble/Sales11.83
Assets/Revenue2.00
Net Working Capital Turnover-7.38
Fixed Assets Turnover0.75
Total Assets Turnover0.5
Revenue per $ Cash54.17
Revenue per $ Plant2.79
Revenue per $ Common Equity7.07
Revenue per $ Capital Invested1.02
Selling, General & Adm/tive (SG&A) as % of Revenue32.2
SG&A Expense as % of Revenue - 5YEAR AVRG.1.0
Research & Devlopment (R&D) as % of Revenue12.6
R&D Expense as % of Revenue - 5YEAR AVRG.12.6

  


Your Recent History
NYSE
GSK
GlaxoSmith..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.


NYSE, AMEX, and ASX quotes are delayed by at least 20 minutes.
All other quotes are delayed by at least 15 minutes unless otherwise stated.